Products and Services
-
CRO OzUK has announced the availability of a new GLP pilot plant designed for pilot and feasibility studies of both solution and suspension MDIs filled with low global warming potential (LGWP) propellants. OzUK announced plans… Read more . . .
-
Intranasal hydrogel maker Polyrizon announced that it has closed a $4.2 million IPO, with a possibility of the total rising to $4.82 million if Aegis Capital exercises an option to purchase additional shares. Polyrizon said… Read more . . .
-
Honeywell announced that it has signed a long-term supply agreement with DevPro Biopharma related to the use of Honeywell’s Solstice Air HFO-1234ze in DevPro’s DP007 albuterol metered dose inhaler. Earlier this year, DevPro and CDMO… Read more . . .
-
Aptar Pharma announced that it has acquired nasal delivery technology from Israeli nasal drug developer SipNose Nasal Delivery Systems. In addition to developing devices, SipNose has a pipeline of candidates developed in-house and candidates in… Read more . . .
-
CDMO Bespak, which spun out from Recipharm earlier this year, and device company H&T Presspart have announced that a new pilot-scale GMP line for filling MDIs with lower global warming potential (LGWP) propellants HFA-152a and HFO-1234ze is ready to… Read more . . .
-
German spray pump manufacturer Aero Pump and soft mist inhaler developer Resyca have announced a partnership for the development and launch of a device called the Ultra Soft Nasal Pump Spray, which is now available… Read more . . .
-
ARS Pharmaceuticals has launched Neffy epinephrine nasal spray in the US, the company said. In Auguest 2024, Neffy was approved by the FDA for the treatment of anaphylaxis in patients who weigh 30 kg or… Read more . . .
-
DPI developer Iconovo said that the FDA “has issued a positive guidance regarding the generic substitutability of the company’s proprietary inhaler ICOpre with the original drug Breo Ellipta with respect to external design and operating… Read more . . .
-
CDMO Ritedose Corporation announced that it will manufacture Verona Pharma’s Ohtuvayre nebulized ensifentrine, which was approved by the FDA in June 2024 for the treatment of COPD. Also in June 2024, Ritedose announced that it… Read more . . .
-
CDMO Serán Bioscience announced “a strategic growth transaction” led by Bain Capital Life Sciences that is worth more than $200 million, with the funds intended to support completion of a new commercial-scale manufacturing facility in… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan